Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma	Not yet recruiting	Phase 2	2026-05-15		NCT07589049

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sun Yat-sen University	606

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Guangdong Medical University	Zhanjiang	China	14
Cancer Hospital of Guangzhou Medical University	Guangzhou	China	2
Cancer Hospital of Shantou University Medical College	Shantou	China	9
Ganzhou Cancer Hospital	Ganzhou	China	3
Guangdong Provincial People's Hospital	Guangzhou	China	59
Guangzhou First People's Hospital	Guangzhou	China	7
Qingyuan People's Hospital	Qingyuan	China	3
Shenzhen Second People's Hospital	Shenzhen	China	17
Sun Yat-Sen University Cancer Center	Guangzhou	China	113
The First People's Hospital of Foshan	Foshan	China	10
The Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	17
ZhuJiang Hospital of Southern Medical University	Guangzhou	China	27